journal
MENU ▼
Read by QxMD icon Read
search

Expert Review of Neurotherapeutics

journal
https://www.readbyqxmd.com/read/28128002/ketamine-for-the-treatment-of-super-refractory-status-epilepticus-not-quite-yet
#1
Frederic Dorandeu
No abstract text is available yet for this article.
February 6, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28132567/will-the-proteus-sensor-enhance-adherence-to-aripiprazole-or-other-antipsychotics
#2
Prakash Masand, Changsu Han, Chi-Un Pae
No abstract text is available yet for this article.
February 3, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28132569/the-challenges-of-developing-a-gene-therapy-for-amyotrophic-lateral-sclerosis
#3
Muhibullah Sayed Tora, Orion Paul Keifer, Jason John Lamanna, Nicholas M Boulis
No abstract text is available yet for this article.
January 30, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28128996/endogenous-repair-and-development-inspired-therapy-of-neurodegeneration-in-progressive-multiple-sclerosis
#4
Ethan Hollingsworth, Jamil Khouri, Jaime Imitola
In recent years, there has been progress in understanding the etiology and immune mechanisms of multiple sclerosis (MS). However, for most, once the diagnosis is made, significant pathology is already present in the central nervous system (CNS), and in many, this leads to neurodegeneration, which accumulates in disability. Although, the mechanisms of such progression are poorly understood, new data suggest lack of remyelination paired with dysfunction of neurons along with stem and progenitor cells as the basis and recent developmental studies suggest that CNS repair processes share mechanisms with development...
January 27, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28092989/therapeutic-complement-inhibition-a-promising-approach-for-treatment-of-neuroimmunological-diseases
#5
Kjara S Pilch, Peter Spaeth, Yuki Nobuhiro, Benjamin R Wakerley
Autoimmunity is an important cause of disease both in the central and peripheral nervous systems. Aetiologies and clinical manifestations are complex and heterogeneous. Inappropriate control of complement activation at inappropriate sites has been recognized as a major determinant in several neurological conditions, including Guillain-Barré syndrome and neuromyelitis optica. In each case pathogenesis is thought to be associated with generation of autoantibodies which upon binding guide activation of the complement system to self-tissue...
January 17, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28092469/investigational-drugs-in-recent-clinical-trials-for-treatment-resistant-depression
#6
Ricardo P Garay, Carlos A Zarate, Thomas Charpeaud, Leslie Citrome, Christoph U Correll, Ahcène Hameg, Pierre-Michel Llorca
The authors describe the medications for treatment-resistant depression (TRD) in phase II/III of clinical development in the EU and USA and provide an opinion on how current treatment can be improved in the near future. Areas covered: Sixty-two trials were identified in US and EU clinical trial registries that included six investigational compounds in recent phase III development and 12 others in recent phase II clinical trials. Glutamatergic agents have been the focus of many studies. A single intravenous dose of the glutamatergic modulator ketamine produces a robust and rapid antidepressant effect in persons with TRD; this effect continues to remain significant for 1 week...
January 29, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/27983884/extra-motor-abnormalities-in-amyotrophic-lateral-sclerosis-another-layer-of-heterogeneity
#7
P A McCombe, N R Wray, R D Henderson
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease defined by the presence of muscle weakness. The motor features of disease are heterogeneous in site of onset and progression. There are also extra-motor features in some patients. The genetic basis for extra-motor features is uncertain. The heterogeneity of ALS is an issue for clinical trials. Areas covered: This paper reviews the range and prevalence of extra-motor features associated with ALS, and highlights the current information about genetic associations with extra-motor features...
January 3, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28005435/is-there-a-weight-neutral-second-generation-antipsychotic-for-bipolar-disorder
#8
Fang Fang, Zuowei Wang, Renrong Wu, Joseph R Calabrese, Keming Gao
Antipsychotic-induced weight gain (WG) and metabolic abnormalities are major concerns. This review was untaken to answer if there is a weight-neutral second-generation antipsychotic for bipolar disorder (BPD). Areas covered: English-language literature in MEDLINE was searched with the keywords of antipsychotic/second-generation antipsychotic or generic/brand name of second-generation antipsychotic, and BPD/mania/depression or bipolar maintenance, and safety/tolerability or WG/weight increase, and randomized, placebo-controlled trial...
January 2, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/27927055/improving-the-therapeutic-efficacy-of-neural-progenitor-cell-transplantation-following-spinal-cord-injury
#9
Michael A Lane, Angelo C Lepore, Itzhak Fischer
There have been a wide range of preclinical studies testing cellular therapies to repair the injured spinal cord, yet they remain a challenge to translate because of inconsistencies in efficacy, limited number of patients with acute/subacute SCI and the high costs of clinical trials. Area covered: This paper focusses on the therapeutic potential of neural precursor cells (NPCs) because they can provide the cellular components capable of promoting repair and enhancing functional improvement following spinal cord injury (SCI)...
December 21, 2016: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/27978768/movement-disorders-and-cerebrovascular-diseases-from-pathophysiology-to-treatment
#10
Stefano Caproni, Carlo Colosimo
Cerebrovascular diseases are one of the most common causes of secondary movement disorders. Hypokinetic or hyperkinetic movement disorders may occur after an ischemic or hemorrhagic stroke, either immediately or thereafter. Such disorders are also known to be caused by diffuse leukoaraiosis, vascular malformations and dural fistulas in the basal ganglia or other brain regions. Area covered: The aim of this review was to describe movement disorders secondary to cerebrovascular diseases, and highlight their pivotal pathophysiological aspects, clinical features, diagnostic criteria and therapeutic options...
December 16, 2016: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/27911120/new-frontiers-in-anticoagulation-non-vitamin-k-oral-anticoagulants-in-stroke-prevention
#11
Valentina Arnao, Marianna Riolo, Antonino Tuttolomondo, Antonio Pinto, Brigida Fierro, Paolo Aridon
Non vitamin-K oral anticoagulants (NOACs) are direct and specific inhibitors of the coagulation factors IIa (dabigatran) and Xa (apixaban, rivaroxaban, edoxaban) which share many pharmacokinetic properties. However, indications are lacking regarding the use of NOACs during thrombolysis, surgery and bleeding events. Areas covered: In this paper, the authors retrospectively analyzed the relevant literature on the NOACs using the PubMed and Google Scholar databases. Expert commentary: Although warfarin is effective in cardioembolic stroke prevention, easier handling and more favorable risk-benefit profile often render NOACs a more preferable therapy choice for neurologists...
December 12, 2016: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/27917685/phosphodiesterase-10-inhibitors-in-clinical-development-for-cns-disorders
#12
Hugo Geerts, Athan Spiros, Patrick Roberts
Phosphodiesterase 10 inhibitors (PDE10-I), are conceptually attractive drugs with a potential great therapeutic window as their enriched striatal localization may likely stimulate D1R and reduce D2R downstream effects. However, so far selective PDE10-I with efficacy in animal models have not shown benefit in clinical trials and unexpectedly revealed a substantial dyskinesia motor side-effect. Areas covered: This paper reviews the underlying biological rationale of PDE10 as a target in schizophrenia, Parkinson's and Huntington's disease based on peer-reviewed published articles, the status of the different PDE10-I in clinical development for various CNS indications and explores possible reasons for the clinical trial failures and translational disconnect...
December 10, 2016: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/27892736/therapeutics-of-postpartum-depression
#13
Michael Thomson, Verinder Sharma
Postpartum depression is a prevalent disorder affecting many women of reproductive age. Despite increasing public awareness, it is frequently underdiagnosed and undertreated leading to significant maternal morbidity and adverse child outcomes. When identified, postpartum depression is usually treated as major depressive disorder. Many studies have identified the postpartum as a period of high risk for first presentations and relapses of bipolar disorder. Areas covered: This article reviews the acute and prophylactic treatment of postpartum major depressive disorder, bipolar depression and major depressive disorder with mixed features...
December 9, 2016: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/27852103/immunological-aspects-of-botulinum-toxin-therapy
#14
Dirk Dressler, Hans Bigalke
Botulinum toxin (BT) is used in many medical specialties to treat muscle hyperactivity, exocrine gland hyperactivity and pain disorders. BT drugs consist of botulinum neurotoxin (BNT), complexing proteins (CP) and excipients. Antibodies can be formed against BNT and CP. When they are formed against BNT (BTAB) they can block BT's therapeutic efficacy thus producing antibody induced therapy failure (ABTF). Areas covered: BT applied and BTAB are in a functional balance within the body. ABTF is rare, but influences the treatment algorithms of BT therapy considerably...
November 28, 2016: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28081625/an-unsound-aan-practice-advisory-on-poststroke-etanercept
#15
Ian A Clark
No abstract text is available yet for this article.
March 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28001435/how-should-physical-exercise-be-used-in-schizophrenia-treatment
#16
Alison R Yung, Joseph Firth
No abstract text is available yet for this article.
March 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/27813429/clinical-utility-of-datscan%C3%A2-imaging-in-the-evaluation-of-patients-with-parkinsonism-a-us-perspective
#17
Stuart H Isaacson, Stanley Fisher, Fiona Gupta, Neal Hermanowicz, Daniel E Kremens, Mark F Lew, Kenneth Marek, Rajesh Pahwa, David S Russell, John Seibyl
Single photon emission computed tomography (SPECT) with Ioflupane I123 injection (DaTscan™) was approved by the Food and Drug Administration in 2011 for striatal dopamine transporter visualization to assist in the evaluation of adult patients with suspected parkinsonian syndromes. While brain SPECT imaging using DaTscan is a covered service under Medicare policy, there is a lack of consensus on its role in routine clinical practice in the US. Areas covered: To address this issue, an expert group of US-based movement disorders neurologists convened to discuss the clinical utility of DaTscan in movement disorders practices within the US...
March 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/27690672/myasthenia-gravis-recent-advances-in-immunopathology-and-therapy
#18
John-Ih Lee, Sebastian Jander
Myasthenia gravis is the most frequent acquired disorder of neuromuscular transmission. In the majority of cases, pathogenic antibodies against components of the postsynaptic muscle endplate membrane can be detected. In recent years there have been significant advances in the pathophysiological understanding and therapy of the disease. Areas covered: PubMed searches were conducted for the term 'myasthenia gravis' cross-referenced with the terms 'immunology', 'subgroups', 'antibody', 'ocular', 'thymoma', 'treatment' and 'thymectomy'...
March 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/27687685/treatment-of-epilepsy-in-patients-with-alzheimer-s-disease
#19
Filippo Sean Giorgi, Melania Guida, Andrea Vergallo, Ubaldo Bonuccelli, Gaetano Zaccara
Epilepsy is significantly more frequent in AD patients than in age-matched controls, even though the true extent of the phenomenon is not clear yet. Areas covered: In this review, we describe in detail the available data on the pharmacological treatment of epilepsy in patients with AD. We also briefly describe general principles of AEDs use in elderly, as well as the potential cognitive profile of AEDs and safety of concomitant psychotropic drugs in patients with epilepsy and AD. Expert commentary: As some preclinical data suggest a role of epileptiform discharges in cognitive decline in AD, a prompt diagnosis and treatment of seizures in these patients should be pursued...
March 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/27677316/perioperative-management-of-parkinson-s-disease
#20
Umer Akbar, Arlet G Kurkchubasche, Joseph H Friedman
Guidelines for the management of Parkinson's disease (PD) patients in the perioperative setting are lacking. Areas covered: Here we review potential problems that may arise when PD patients are undergoing an operation. We also review the literature, where available, and provide our expert opinion and recommendations based on experience. Expert commentary: Elderly patients with PD are especially prone to complications in the perioperative setting. Extreme caution must be used to ensure appropriate medication administration, transition to non-oral agents, if indicated, and early mobilization to achieve rapid recovery after surgery...
March 2017: Expert Review of Neurotherapeutics
journal
journal
39882
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"